ACTIVE_NOT_RECRUITING

Mindfulness-Oriented Recovery Enhancement (MORE) in Heroin Addiction

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

In this study, neuroimaging of reward processing, drug cue reactivity and inhibitory control is used before and immediately after 8 weeks of two types of group therapy in individuals with opioid addiction; clinical outcomes will be assessed before, immediately and three months after treatment. Results could point to factors that track and predict recovery with treatment, offering clinicians markers that can be used for enhancing precision medicine with the goal of reducing morbidity and mortality associated with opiate addiction.

Official Title

Neuroimaging Response Inhibition and Salience Attribution Changes During Mindfulness-based Treatment of Human Heroin Addiction

Quick Facts

Study Start:2020-06-21
Study Completion:2031-03-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT04112186

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 64 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Ability to understand and give informed consent
  2. * Males and Females 18-64 years of age
  3. * DSM-5 diagnosis of OUD with heroin as the primary drug of choice
  4. * Stabilized on methadone or other form of MAT.
  1. * DSM-5 diagnosis for schizophrenia or developmental disorder (e.g., autism)
  2. * Head trauma with loss of consciousness
  3. * History of neurological disease of central origin including seizures
  4. * Cardiovascular disease including high blood pressure and/or other medical conditions, including metabolic, endocrinological,oncological or autoimmune diseases, and infectious diseases common in iOUD including Hepatitis B and C or HIV/AIDS
  5. * Metal implants or other MR contraindications

Contacts and Locations

Principal Investigator

Rita Goldstein, PhD
PRINCIPAL_INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Nelly Alia-Klein, PhD
STUDY_DIRECTOR
Icahn School of Medicine at Mount Sinai

Study Locations (Sites)

Icahn School of Medicine at Mount Sinai
New York, New York, 10029
United States

Collaborators and Investigators

Sponsor: Icahn School of Medicine at Mount Sinai

  • Rita Goldstein, PhD, PRINCIPAL_INVESTIGATOR, Icahn School of Medicine at Mount Sinai
  • Nelly Alia-Klein, PhD, STUDY_DIRECTOR, Icahn School of Medicine at Mount Sinai

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-06-21
Study Completion Date2031-03-31

Study Record Updates

Study Start Date2020-06-21
Study Completion Date2031-03-31

Terms related to this study

Keywords Provided by Researchers

  • Mindfulness
  • Opiate Use Disorder
  • Drug Cue Reactivity
  • Inhibitory Control
  • Salience Attribution

Additional Relevant MeSH Terms

  • Opiate Use Disorder